Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China
|
MSCI China Small-Cap
|
Hang Seng Index
|
Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
    • China ESG Focus
  • Fast News
  • Expert Corner
  • Audio/Video
  • IPO
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
    • China ESG Focus
  • Fast News
  • Expert Corner
  • Audio/Video
  • IPO
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Walvax Biotechnology

CanSino gets most of its revenue from meningitis shots

Meningitis shot delivers dose of good cheer for CanSino

The company has defied a broader slowdown in the vaccine industry with its latest earnings report, after its flagship drug was cleared for use in a wider age group Key…
March 5, 2026
6185.HK
688185.SHG

CSPC Pharma wins China’s mRNA vaccine race, but just not fast enough

Drugmaker CSPC Pharma gets the green light to produce China’s first homegrown mRNA vaccine, but the breakthrough comes too late in the pandemic to impress investors Key Takeaways: News of…
March 29, 2023
1093.HK

After Ditching Promising Drug, Everest Medicines Bets on mRNA

The drug maker surprised investors last year when it halted its tie-up with Gilead to develop the breast cancer drug Trodelvy. Now it says it will focus on mRNA vaccinesKey…
January 12, 2023

Recent Articles

CanSino gets most of its revenue from meningitis shots
March 5, 2026

Meningitis shot delivers dose of good cheer for CanSino

6185.HK
688185.SHG
March 29, 2023

CSPC Pharma wins China’s mRNA vaccine race, but just not fast enough

1093.HK
January 12, 2023

After Ditching Promising Drug, Everest Medicines Bets on mRNA

RELATED ARTICLES

  1. Meituan does instant commerce
    February 16, 2026
    Instant commerce war delivers massive loss to Meituan
    3690.HK
  2. February 24, 2026
    Fading interest in animal health takes bite out of Sinder
  3. December 9, 2025
    Stumbling Transsion calls on Hong Kong investors. But will they answer?
    688036.SHG
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2026 Bamboo Works. All rights reserved.